(MLTX) MoonLake Immunotherapeutics - Overview
Exchange: NASDAQ •
Country: Switzerland •
Currency: USD •
Type: Common Stock •
ISIN: KY61559X1045
Stock: Sonelokimab, Nanobody, IL-17A, IL-17F
Total Rating 16
Risk 35
Buy Signal -0.46
| Risk 5d forecast | |
|---|---|
| Volatility | 68.9% |
| Relative Tail Risk | -8.09% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.42 |
| Alpha | -78.73 |
| Character TTM | |
|---|---|
| Beta | 0.684 |
| Beta Downside | 0.463 |
| Drawdowns 3y | |
|---|---|
| Max DD | 90.22% |
| CAGR/Max DD | 0.02 |
Description: MLTX MoonLake Immunotherapeutics January 10, 2026
MoonLake Immunotherapeutics (NASDAQ: MLTX) is a clinical-stage biotech founded in 2021 and based in Zug, Switzerland. Its lead asset, Sonelokimab, is a tri-specific Nanobody that simultaneously blocks IL-17A and IL-17F, targeting inflammatory skin and joint conditions such as hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and plaque psoriasis.
Key metrics as of the latest quarterly filing show a cash runway of roughly $45 million, sufficient to fund Phase 2 trials through late 2025, and a market-size estimate of $15-$20 billion for IL-17-targeted therapies worldwide. The company’s valuation is heavily influenced by the broader biotech funding environment-venture capital and public market liquidity have been volatile in 2023-24-and by competitive dynamics, notably the dominance of AbbVie’s Humira and Eli Lilly’s Taltz in the same therapeutic space.
For a data-driven deep-dive into MLTX’s risk-adjusted upside, you may find ValueRay’s analytical platform useful.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -210.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.45 > 0.02 and ΔFCF/TA -29.22 > 1.0 |
| NWC/Revenue: 356.3k% < 20% (prev 1.25m%; Δ -890.7k% < -1%) |
| CFO/TA -0.45 > 3% & CFO -185.7m > Net Income -210.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.50 > 1.5 & < 3 |
| Outstanding Shares: last quarter (63.4m) vs 12m ago 0.75% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.02% > 50% (prev 0.01%; Δ 0.01% > 0%) |
| Interest Coverage Ratio: -40.22 > 6 (EBITDA TTM -208.1m / Interest Expense TTM 5.25m) |
Altman Z'' -3.86
| A: 0.88 (Total Current Assets 411.2m - Total Current Liabilities 48.4m) / Total Assets 414.3m |
| B: -0.97 (Retained Earnings -400.5m / Total Assets 414.3m) |
| C: -0.45 (EBIT TTM -211.3m / Avg Total Assets 466.3m) |
| D: -3.25 (Book Value of Equity -400.2m / Total Liabilities 123.1m) |
| Altman-Z'' Score: -3.86 = D |
Beneish M -2.63
| DSRI: 0.65 (Receivables 4.02m/2.41m, Revenue 101.8k/39.5k) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.36 (AQ_t 0.00 / AQ_t-1 0.00) |
| SGI: 2.58 (Revenue 101.8k / 39.5k) |
| TATA: -0.06 (NI -210.5m - CFO -185.7m) / TA 414.3m) |
| Beneish M-Score: -2.63 (Cap -4..+1) = A |
What is the price of MLTX shares?
As of February 07, 2026, the stock is trading at USD 15.51 with a total of 861,717 shares traded.
Over the past week, the price has changed by -1.02%, over one month by +38.85%, over three months by +50.73% and over the past year by -67.08%.
Over the past week, the price has changed by -1.02%, over one month by +38.85%, over three months by +50.73% and over the past year by -67.08%.
Is MLTX a buy, sell or hold?
MoonLake Immunotherapeutics has received a consensus analysts rating of 4.75.
Therefore, it is recommended to buy MLTX.
- StrongBuy: 12
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the MLTX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 18.6 | 20.1% |
| Analysts Target Price | 18.6 | 20.1% |
| ValueRay Target Price | 14.7 | -5.2% |
MLTX Fundamental Data Overview February 03, 2026
P/B = 3.9751
Revenue TTM = 101.8k USD
EBIT TTM = -211.3m USD
EBITDA TTM = -208.1m USD
Long Term Debt = 73.7m USD (from longTermDebt, last quarter)
Short Term Debt = 1.50m USD (from shortTermDebt, last quarter)
Debt = 75.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -275.0m USD (from netDebt column, last quarter)
Enterprise Value = 805.4m USD (1.11b + Debt 75.7m - CCE 380.5m)
Interest Coverage Ratio = -40.22 (Ebit TTM -211.3m / Interest Expense TTM 5.25m)
EV/FCF = -4.33x (Enterprise Value 805.4m / FCF TTM -185.9m)
FCF Yield = -23.08% (FCF TTM -185.9m / Enterprise Value 805.4m)
FCF Margin = -182.5k% (FCF TTM -185.9m / Revenue TTM 101.8k)
Net Margin = -206.7k% (Net Income TTM -210.5m / Revenue TTM 101.8k)
Gross Margin = unknown ((Revenue TTM 101.8k - Cost of Revenue TTM 1.92m) / Revenue TTM)
Tobins Q-Ratio = 1.94 (Enterprise Value 805.4m / Total Assets 414.3m)
Interest Expense / Debt = 4.22% (Interest Expense 3.20m / Debt 75.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = -166.9m (EBIT -211.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.50 (Total Current Assets 411.2m / Total Current Liabilities 48.4m)
Debt / Equity = 0.26 (Debt 75.7m / totalStockholderEquity, last quarter 288.9m)
Debt / EBITDA = 1.32 (negative EBITDA) (Net Debt -275.0m / EBITDA -208.1m)
Debt / FCF = 1.48 (negative FCF - burning cash) (Net Debt -275.0m / FCF TTM -185.9m)
Total Stockholder Equity = 374.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -45.14% (Net Income -210.5m / Total Assets 414.3m)
RoE = -56.25% (Net Income TTM -210.5m / Total Stockholder Equity 374.2m)
RoCE = -47.16% (EBIT -211.3m / Capital Employed (Equity 374.2m + L.T.Debt 73.7m))
RoIC = -38.88% (negative operating profit) (NOPAT -166.9m / Invested Capital 429.3m)
WACC = 8.10% (E(1.11b)/V(1.19b) * Re(8.43%) + D(75.7m)/V(1.19b) * Rd(4.22%) * (1-Tc(0.21)))
Discount Rate = 8.43% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.84%
Fair Price DCF = unknown (Cash Flow -185.9m)
EPS Correlation: -44.98 | EPS CAGR: 10.36% | SUE: 4.0 | # QB: 1
Revenue Correlation: 25.76 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.89 | Chg30d=+0.003 | Revisions Net=+1 | Analysts=4
EPS next Year (2026-12-31): EPS=-3.76 | Chg30d=-0.181 | Revisions Net=+1 | Growth EPS=-4.3% | Growth Revenue=+0.0%
Revenue TTM = 101.8k USD
EBIT TTM = -211.3m USD
EBITDA TTM = -208.1m USD
Long Term Debt = 73.7m USD (from longTermDebt, last quarter)
Short Term Debt = 1.50m USD (from shortTermDebt, last quarter)
Debt = 75.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -275.0m USD (from netDebt column, last quarter)
Enterprise Value = 805.4m USD (1.11b + Debt 75.7m - CCE 380.5m)
Interest Coverage Ratio = -40.22 (Ebit TTM -211.3m / Interest Expense TTM 5.25m)
EV/FCF = -4.33x (Enterprise Value 805.4m / FCF TTM -185.9m)
FCF Yield = -23.08% (FCF TTM -185.9m / Enterprise Value 805.4m)
FCF Margin = -182.5k% (FCF TTM -185.9m / Revenue TTM 101.8k)
Net Margin = -206.7k% (Net Income TTM -210.5m / Revenue TTM 101.8k)
Gross Margin = unknown ((Revenue TTM 101.8k - Cost of Revenue TTM 1.92m) / Revenue TTM)
Tobins Q-Ratio = 1.94 (Enterprise Value 805.4m / Total Assets 414.3m)
Interest Expense / Debt = 4.22% (Interest Expense 3.20m / Debt 75.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = -166.9m (EBIT -211.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.50 (Total Current Assets 411.2m / Total Current Liabilities 48.4m)
Debt / Equity = 0.26 (Debt 75.7m / totalStockholderEquity, last quarter 288.9m)
Debt / EBITDA = 1.32 (negative EBITDA) (Net Debt -275.0m / EBITDA -208.1m)
Debt / FCF = 1.48 (negative FCF - burning cash) (Net Debt -275.0m / FCF TTM -185.9m)
Total Stockholder Equity = 374.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -45.14% (Net Income -210.5m / Total Assets 414.3m)
RoE = -56.25% (Net Income TTM -210.5m / Total Stockholder Equity 374.2m)
RoCE = -47.16% (EBIT -211.3m / Capital Employed (Equity 374.2m + L.T.Debt 73.7m))
RoIC = -38.88% (negative operating profit) (NOPAT -166.9m / Invested Capital 429.3m)
WACC = 8.10% (E(1.11b)/V(1.19b) * Re(8.43%) + D(75.7m)/V(1.19b) * Rd(4.22%) * (1-Tc(0.21)))
Discount Rate = 8.43% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.84%
Fair Price DCF = unknown (Cash Flow -185.9m)
EPS Correlation: -44.98 | EPS CAGR: 10.36% | SUE: 4.0 | # QB: 1
Revenue Correlation: 25.76 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.89 | Chg30d=+0.003 | Revisions Net=+1 | Analysts=4
EPS next Year (2026-12-31): EPS=-3.76 | Chg30d=-0.181 | Revisions Net=+1 | Growth EPS=-4.3% | Growth Revenue=+0.0%